Skip to content
MS
PW-041 Lipid Metabolism Anabolic unreviewed

Sphingolipid Synthesis

Serine + palmitoyl-CoA Ceramide -> sphingomyelin, cerebrosides, gangliosides
Compartment
ER + Golgi
Main tissue
Nervous tissue, all cells
Rate-limiting
Serine palmitoyltransferase (SPT)
Steps
6

Reaction steps

In source order, 6 total

showing 1–6
  1. 1

    Serine + palmitoyl-CoA -> 3-ketosphinganine + CO2 + CoA-SH

    Serine palmitoyltransferase (SPT) 2.3.1.50 ST-0324 Irreversible rate-limiting PLP (B6)
    › Notes

    Rate-limiting and committed step; located on the ER.

  2. 2

    3-Ketosphinganine + NADPH -> sphinganine + NADP+

    3-Ketosphinganine reductase 1.1.1.102 ST-0325 Irreversible/directional NADPH
  3. 3

    Sphinganine + fatty acyl-CoA -> dihydroceramide + CoA-SH

    Ceramide synthase (CerS1-6) 2.3.1.24 ST-0326 Irreversible/directional
    › Notes

    Six isoforms determine the acyl chain length of the ceramide pool.

  4. 4

    Dihydroceramide -> ceramide

    › Notes

    Ceramide is the hub metabolite of all complex sphingolipids and a pro-apoptotic signal.

  5. 5

    Ceramide + phosphatidylcholine -> sphingomyelin + diacylglycerol

    Sphingomyelin synthase (SGMS1/2) 2.7.8.27 ST-0328 Irreversible/directional
    › Notes

    Occurs in the Golgi; sphingomyelin is a major myelin and plasma-membrane lipid.

  6. 6

    Ceramide + UDP-glucose -> glucosylceramide + UDP

    › Notes

    Entry to the glycosphingolipid/ganglioside series; sequential glycosyltransferases then build lactosylceramide, globosides and gangliosides.

Showing all 6 steps.

Recent literature

Live Europe PMC search

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Non-ergosterol lipid remodeling governs amphotericin B susceptibility via TOR-calcineurin signaling in <i>Candida glabrata</i>.

    Kumar M, Kumari S, Wasi M, Ali B, Kumar P, Sharma G, Singh A, da Silva Dantas A, Gow NAR, Gaur NA, Prasad R. · 2026-08-26

    open access unreviewed
  2. 2
  3. 3
    Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib.

    Huang F, Zhan P, Shi X, Sun Y, Song X, Sun P, Liu B. · 2026-05-22

    open access unreviewed
  4. 4
    The responsive nucleus: morphological signatures of cellular state.

    Pérez-Venteo A, Bosch-Calvet M, Garcia-Cajide M, Mauvezin C. · 2026-02-19

    cited 4× open access unreviewed
  5. 5
    Role of lipid-associated fibroblasts and their signature genes FABP4, CD36 and ABCA8 in gastric cancer progression.

    Liao J, Wu L, Zhou L, Ling Q, Zhang P. · 2026-07-30

    open access unreviewed
  6. 6
    Lysosomal metabolism in pancreatic cancer and its crosstalk with host physiology.

    Cheng C, Pakkan R, Chinnaiyan AM, Lyssiotis CA. · 2026-10-01

    open access unreviewed
  7. 7
    Metabolic determinants of autoimmune kidney diseases.

    Scindia Y, Morel L. · 2026-07-06

    unreviewed
  8. 8
    Proteomic Analysis of Sphingolipid Metabolic Enzymes with Risk of Bladder Cancer Incidence and Mortality in the Atherosclerosis Risk in Communities Study.

    Marrone MT, Bagley E, Butler KR, Couper DJ, Joshu CE, Platz EA, Ogretmen B. · 2026-10-01

    unreviewed
  9. 9
    The role of sphingolipids in major depressive disorder and associated cognitive impairment: interactions with monoaminergic signaling, neuroinflammation, and neurogenesis.

    Hoertel N, Mühle C, Müller CP, Chaieb H, Scheer V, Fayad M, Sánchez-Rico M, Limosin F, Kornhuber J. · 2026-05-13

    cited 1× open access unreviewed
  10. 10

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.